Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507693 | 0.92 | L3MBTL1 (0.40) | MAPK1HSD17B10TSHRKDM4ERAB9A | |
| SCHEMBL3511132 | 0.91 | KMT2A (0.39) | MAPK1HSD17B10TSHRKDM4ERAB9A | |
| SCHEMBL1003348 | 0.89 | CDK2 (0.44) | MAPK1HSD17B10TSHRKDM4ERAB9A | |
| SCHEMBL12311487 | 0.87 | F10 (0.46) | MAPK1HSD17B10TSHRKDM4ERAB9A | |
| SCHEMBL3507730 | 0.86 | F10 (0.45) | MAPT | |
| SCHEMBL1001613 | 0.85 | GAA (0.39) | KDM4EKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL1003236 | 0.84 | CDK2 (0.40) | MAPK1HSD17B10TSHRKDM4ERAB9A | |
| SCHEMBL1002607 | 0.83 | NPC1 (0.37) | TSHRKDM4ERAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1002768 | 0.82 | RAB9A (0.34) | MAPK1HSD17B10TSHRKDM4ERAB9A | |
| SCHEMBL3510539 | 0.82 | F10 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263624-B2 | Aryl-substituted heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263624-B2 | Aryl-substituted heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263624-B2 | Aryl-substituted heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20100029651-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | BAYER HEALTHCARE AG | 2010-02-04 | — | — | US | disclosed |
| US-20100029651-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | BAYER HEALTHCARE AG | 2010-02-04 | — | — | US | disclosed |
| US-20100029651-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | BAYER HEALTHCARE AG | 2010-02-04 | — | — | US | disclosed |
| WO-2007137791-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007137792-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | F2, VKORC1, HMBS | MAPK1 2788/4885HSD17B10 660/4885TSHR 2267/4885 |
| US-20100029651-A1 | ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF | AHR, CYP2C19, PAH | MAPK1 1980/4885HSD17B10 935/4885TSHR 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.